Kupando has raised an additional €10M in Series A financing, bringing its total to €23M, to fund Phase 1b trials of KUP101.
Kupando raised an additional €10 million in Series A financing, bringing the total Series A funding to €23 million.Investment again led by Remiges Ventures, co-led by LifeCare Partners, with ...
Researchers have deciphered the complex interplay of various enzymes around the innate immune receptor toll-like receptor 7 (TLR7), which plays an important role in defending our bodies against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results